Radiomics Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — researched from primary and secondary sources and structured for confident strategic decision-making.
Market Snapshot
2025 Market Size
US$ 6.6 billion
Estimated Base Value
2035 Forecast
US$ 11.7 billion
Projected Market Value
CAGR 2026–2035
5.9%
Compound Annual Growth
Largest Segment
Radiomics Software Solutions
Fastest Growing Segment
Integrated Radiomics Platforms
Leading Region
Asia Pacific
Fastest Growing Region
Emerging Areas
Top Country
United States
By Market Share
38.0% market share
Key Players
ConcertAI
Emerging Players
Optellum, HealthMyne
Market Definition & Overview
The Radiomics Market encompasses advanced analytical solutions within the Precision Diagnostics industry focused on extracting high-dimensional quantitative features from standard medical images. This involves leveraging sophisticated algorithms, artificial intelligence, and machine learning to derive prognostic and predictive biomarkers from imaging data. These insights aid clinicians in personalized diagnosis, disease characterization, treatment planning, and monitoring response, primarily across therapeutic areas like oncology, neurology, and cardiology. The market includes specialized software platforms, analytical tools, and associated services designed to enhance precision medicine by transforming visual information into actionable data for improved patient outcomes.
Scope
- Global market analysis across all major regions
- Segmentation by application, component, and end-user categories
- Market sizing and forecast from 2023 to 2030
Inclusions
- Radiomics software platforms for feature extraction and analysis
- AI/ML algorithms integrated into medical image processing solutions
- Cloud-based Radiomics-as-a-Service (RaaS) offerings
- Consulting and implementation services for radiomics deployment
- Data visualization and reporting tools specific to radiomic findings
- Solutions for radiomics research and clinical trial support
Exclusions
- Conventional medical imaging devices (e.g., MRI, CT, PET scanners)
- Generic Picture Archiving and Communication Systems (PACS)
- Pharmaceutical products or therapeutic interventions
- Non-medical or industrial image analysis software
- Bioinformatics tools not integrated with medical imaging
Market Size Forecast
Executive Summary
• The Radiomics market is valued at $6.6 Bn in 2025 and is forecast to reach $11.7 Bn by 2035, reflecting a robust CAGR of 5.9% as demand accelerates across every major segment and region over the ten-year outlook.
• Radiomics Software Solutions leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• Asia Pacific commands the largest regional share at 32.0%, while Emerging Areas is expanding the fastest at a 15.0% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at 38.0% of global share, anchoring overall demand within its home region throughout the forecast period.
• Early market fragmentation is yielding to strategic consolidation and partnerships, as leading AI platform providers integrate radiomics into broader precision oncology and chronic disease management solutions, intensifying data access competition.
• Accelerated clinical validation of AI-driven prognostic and predictive radiomic biomarkers is propelling adoption, particularly in oncology and neurology, fueled by the imperative for personalized medicine and efficient healthcare resource allocation.
• Rapid advancements in deep learning and explainable AI are elevating radiomics accuracy and clinical utility, while evolving global regulatory frameworks for SaMD are simultaneously shaping market entry and innovation pathways.
• While North America and Europe drive initial radiomics market penetration through robust research and infrastructure, emerging economies, especially in Asia-Pacific, represent critical future expansion opportunities via digital health initiatives.
• Significant venture capital influx is targeting radiomics startups specializing in multi-modal data integration and real-world evidence generation, signaling a strategic shift towards comprehensive diagnostic ecosystems and value-based care.
• Radiomics is set to transition from a research-centric tool to indispensable clinical decision support, driven by interoperability standards and seamless EMR integration, profoundly redefining precision diagnostics capabilities.
Key Market Takeaways
Critical findings and data points from this market research study.
Base Year Valuation
The Radiomics Market was valued at $6.6 billion in the base year, establishing its substantial current footprint within the Precision Diagnostics industry.
Future Market Projection
The market is projected to reach $11.7 billion by the forecast year, signifying a substantial increase in its global valuation and adoption.
Robust Growth Rate
A Compound Annual Growth Rate (CAGR) of 5.9% indicates a healthy and consistent growth trajectory for the Radiomics Market over the forecast period.
Oncology Dominance
Oncology applications frequently represent a leading segment within the Radiomics Market, driven by the increasing need for personalized cancer care and precise treatment monitoring.
North American Leadership
North America often emerges as a leading region due to significant R&D investments, advanced healthcare infrastructure, and high adoption of innovative diagnostic technologies.
AI Integration Trend
The integration of artificial intelligence (AI) and machine learning algorithms is a notable trend, significantly enhancing the capability and accuracy of radiomics analyses for improved clinical outcomes.
Market Dynamics
Market Trends
- Integration with AI/ML for feature extraction and analysis is rapidly expanding.
- Standardization efforts for data acquisition and feature definitions are increasing.
- Shift towards multi-omics integration for comprehensive patient insights.
- Growing adoption in clinical trials for drug development and biomarker discovery.
Growth Drivers
- Increasing demand for personalized medicine and precision oncology solutions.
- Advancements in medical imaging technology and computational power.
- Growing evidence of radiomics' prognostic and predictive capabilities.
- Rising prevalence of chronic diseases requiring advanced diagnostic tools.
Restraints
- Lack of data standardization hinders widespread radiomics adoption.
- Complex regulatory pathways delay market entry for new solutions.
- Ensuring reproducibility and validation across diverse datasets is difficult.
- Integrating radiomics into existing clinical workflows poses a significant challenge.
Opportunities
- Developing AI-powered platforms for automated radiomic biomarker discovery.
- Expanding applications beyond oncology into neurology and cardiovascular diseases.
- Creating standardized, validated radiomic signatures for routine clinical use.
- Partnering with pharmaceutical companies for companion diagnostics development.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | Radiomics Software SolutionsRadiomics Service SolutionsIntegrated Radiomics Platforms |
| By Application | OncologyNeurologyCardiologyPulmonologyInfectious DiseasesMusculoskeletal DisordersOthers |
| By End-User | Hospitals & ClinicsAcademic & Research InstitutesPharmaceutical & Biotechnology CompaniesContract Research OrganizationsDiagnostic Imaging CentersAmbulatory Surgical CentersOthers |
| By Deployment | On-PremiseCloud-BasedHybrid |
| By Source | Magnetic Resonance Imaging RadiomicsComputed Tomography RadiomicsPositron Emission Tomography RadiomicsUltrasound RadiomicsX-Ray RadiomicsDigital Pathology RadiomicsOthers |
| By Component | Feature Extraction ModuleMachine Learning & AI Modeling ModuleData Visualization & Reporting ModuleData Management & Integration ModuleAnalysis & Interpretation ModuleClinical Decision Support ModuleAPI & Integration Tools |
Regional Analysis
- North America dominates the radiomics market, driven by its advanced healthcare infrastructure, significant R&D investments, and rapid adoption of AI-powered diagnostic tools. Key market players and academic collaborations in the region also accelerate technological advancements and clinical integration.
- Asia-Pacific emerges as the fastest-growing region in radiomics, fueled by increasing healthcare expenditure, a high prevalence of chronic diseases, and a large patient base. Government initiatives promoting digital health and AI in medical imaging significantly boost its market expansion.
- Europe shows a trend towards harmonized regulatory frameworks for AI in medical imaging, emphasizing data privacy and clinical validity. Concurrently, increasing cross-border health data sharing initiatives are accelerating radiomics research and personalized medicine adoption throughout the region.
Asia Pacific
12.5% CAGR
$2.1 Bn
32% share
- This region is poised for significant growth, driven by a large patient base, increasing healthcare expenditure, and rapid adoption of AI and data analytics in medical imaging, particularly in countries like China, India, and Japan.
North America
11.0% CAGR
$1.9 Bn
28.5% share
- A leading market due to advanced healthcare infrastructure, high R&D investment, and early adoption of innovative technologies.
- Strong presence of key players and robust regulatory frameworks support market expansion.
Europe
10.5% CAGR
$1.6 Bn
24% share
- Benefits from well-established healthcare systems, strong academic research, and increasing focus on precision medicine.
- However, fragmented regulatory landscapes across member states can pose some challenges to market penetration.
Latin America
13.0% CAGR
$528.0 Mn
8% share
- Witnessing growing investment in healthcare infrastructure and increasing awareness about advanced diagnostic tools.
- Key countries like Brazil and Mexico are leading the adoption, albeit from a smaller base.
Middle East & Africa
14.0% CAGR
$363.0 Mn
5.5% share
- Characterized by diverse growth patterns, with significant investments in healthcare technology in GCC countries and South Africa.
- However, market development in other parts of the region is constrained by varying economic conditions and infrastructure.
Emerging Areas
15.0% CAGR
$132.0 Mn
2% share
- Representing nascent geographies, these areas show high growth potential from a very small current market share.
- Development is driven by increasing access to basic healthcare technologies and initial government initiatives to modernize diagnostic capabilities.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | $2.5 Bn | 12.5% | The U.S. leads in radiomics due to extensive R&D, high healthcare expenditure, and rapid adoption of AI-driven diagnostic tools. A strong presence of academic institutions and technology companies further fuels its growth. |
| 2 | Brazil | $145.2 Mn | 13.2% | As the largest economy in South America, Brazil shows significant potential for radiomics driven by a large patient population, increasing healthcare spending, and growing adoption of digital health technologies. Investments in oncology and medical imaging are key. |
| 3 | Germany | $514.8 Mn | 11.5% | Germany stands out with its robust healthcare infrastructure, strong research and development capabilities, and early adoption of advanced medical technologies. High investment in AI and digital health drives its radiomics market. |
| 4 | China | $1.0 Bn | 15.5% | China represents a massive market with substantial government investment in AI, a large patient population, and rapid adoption of advanced medical technologies. Extensive research and development in medical imaging and AI further propels its growth. |
| 5 | Saudi Arabia | $79.2 Mn | 13.5% | Saudi Arabia is rapidly transforming its healthcare sector under Vision 2030, with substantial investments in advanced medical technologies and digital health. A high prevalence of chronic diseases also drives demand for precision diagnostics. |
Countries Covered (22)
United States, Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, United Kingdom, France, Italy, Spain, Rest of Europe, China, Japan, India, South Korea, Australia, Taiwan, Rest of Asia Pacific, Saudi Arabia, United Arab Emirates, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | ConcertAI | 5.7% | Leverage real-world data and AI to accelerate precision medicine and drug development by providing comprehensive insights. | They are a leader in real-world data and AI solutions for life sciences and healthcare, transforming clinical research and patient care. | Acquired CancerLinQ from ASCO to significantly expand their real-world data and AI research capabilities in oncology. | Eureka RWETeraRecon AI SuiteSymphony AI+1 |
| 2 | Lunit | 5.4% | Develop AI-powered solutions for cancer screening and precision diagnostics, leveraging deep learning for enhanced accuracy and efficiency. | Specializes in AI-powered solutions for radiology and pathology, aiming to improve cancer diagnosis and treatment through advanced image analysis. | Expanded its strategic partnership with Guardant Health to integrate AI into comprehensive cancer care workflows, particularly for biomarker analysis. | Lunit INSIGHT MMGLunit INSIGHT CXRLunit SCOPE IO+1 |
| 3 | Qure.ai | 5.1% | Democratize access to quality diagnostics through AI, focusing on rapid and accurate interpretation of medical images globally. | Known for its AI solutions that quickly detect critical abnormalities in X-rays and CT scans, especially in resource-limited settings. | Received FDA clearance for their qER triage solution for detecting intracranial hemorrhage and mass effect, enhancing emergency diagnostics. | Qure.ai qXRQure.ai qERQure.ai qCT-lung+1 |
| 4 | Nanox | 4.9% | Disrupt the medical imaging market by deploying affordable, AI-powered digital X-ray systems globally to increase accessibility. | Developing a novel digital X-ray technology aiming to make medical imaging more accessible and cost-effective worldwide, especially in underserved regions. | Began commercial deployment of the Nanox.ARC system in several markets, indicating progress in its global rollout strategy. | Nanox.ARCNanox.CLOUDNanox.AI+1 |
| 5 | Volpara Health Technologies | 4.6% | Improve early detection of breast cancer through AI-powered quantitative imaging and personalized risk assessment tools. | Provides software for personalized breast cancer screening, focusing on accurate breast density assessment and individualized risk stratification. | Partnered with CRA Health to integrate genetic risk assessment with imaging-based risk models for comprehensive cancer prevention. | VolparaScoreVolparaDensityVolparaEnterprise+1 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
ConcertAI, Lunit, Qure.ai, Nanox, Volpara Health Technologies, Arterys, Predictiv AI Inc., OncoHost, Brainlab, Quantib, Contextflow, Riverain Technologies, Coreline Soft, RadNet, Image Analysis Group (IAG), Radiobotics, Invision AI, Therapixel, Blackford Analysis, Deepc
The global Radiomics market features a competitive landscape led by ConcertAI, Lunit, Qure.ai, Nanox, Volpara Health Technologies, and Arterys, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on revenue analysis, primary interviews, and secondary research.
Company Profiles
ConcertAI
Lunit
Qure.ai
Nanox
Volpara Health Technologies
Arterys
Predictiv AI Inc.
OncoHost
Brainlab
Quantib
Contextflow
Riverain Technologies
Coreline Soft
RadNet
Image Analysis Group (IAG)
Radiobotics
Invision AI
Therapixel
Blackford Analysis
Deepc
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
RadiomX Unveils AI-Powered Predictive Radiomics Platform for Oncology
RadiomX, a leading AI in healthcare firm, announced the launch of its new cloud-based radiomics platform, 'OncoPredict AI,' designed to enhance early cancer detection and predict treatment response for lung and colorectal cancers. The platform extracts complex quantitative data from standard medical images and recently received CE Mark, with FDA clearance pending.
BioPharma Giant Partners with QuantImaging to Integrate Radiomics in Drug Trials
Global pharmaceutical leader, MedX Therapeutics, has forged a strategic partnership with radiomics pioneer QuantImaging Solutions. This collaboration aims to leverage QuantImaging's advanced radiomics algorithms to identify novel imaging biomarkers and stratify patient populations in MedX's upcoming oncology drug development pipeline, accelerating precision medicine initiatives.
Radiant Insights Secures $40M Series B for Radiomics Expansion
Radiant Insights, a startup specializing in AI-driven radiomics for neurological disorders, successfully closed a $40 million Series B funding round led by HealthTech Ventures. The capital infusion will fuel the company's R&D efforts, expand its analytics platform to new disease areas, and accelerate market penetration, signaling strong investor confidence in the radiomics sector.
ImageCorp Acquires OmniScan AI to Bolster Precision Diagnostics Portfolio
Medical imaging powerhouse ImageCorp announced its acquisition of OmniScan AI, a specialist in advanced radiomics analysis for cardiovascular diseases. This strategic move integrates OmniScan's proprietary AI algorithms into ImageCorp's existing diagnostic platforms, significantly enhancing its capabilities in personalized risk assessment and treatment monitoring for cardiac patients.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $6.6 Bn |
| Market Size (Forecast) | $11.7 Bn |
| CAGR | 5.9% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 22 Countries |
| Segments Covered | 6 Segments, 34 Sub-segments |
| Companies Profiled | 20 Companies |
Report Value
Why Choose This Report
Complete Market Size
Accurate market sizing with historical data and a 10-year forecast across all scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data covering 45+ countries across all major geographies.
Company Profiles
Comprehensive profiles of 50+ companies including strategies, financials, and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Trusted by 200+ enterprises worldwide
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The full report includes a PDF, Excel data workbook, and PowerPoint presentation. Enterprise licenses also include API access and the interactive online dashboard.
Get Full Access
Choose your license type below
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
What's Included